Lauren P. Silvernail
2017
In 2017, Lauren P. Silvernail earned a total compensation of $1.6M as Former Chief Financial Officer and Chief Business Officer at Revance Therapeutics, a 4% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $157,219 |
|---|---|
| Option Awards | $737,668 |
| Salary | $442,900 |
| Stock Awards | $197,000 |
| Other | $67,370 |
| Total | $1,602,157 |
Silvernail received $737.7K in option awards, accounting for 46% of the total pay in 2017.
Silvernail also received $157.2K in non-equity incentive plan, $442.9K in salary, $197K in stock awards and $67.4K in other compensation.
Rankings
In 2017, Lauren P. Silvernail's compensation ranked 6,637th out of 14,666 executives tracked by ExecPay. In other words, Silvernail earned more than 54.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,637 out of 14,666 | 55th |
Division Manufacturing | 2,456 out of 5,768 | 57th |
Major group Chemicals And Allied Products | 791 out of 2,074 | 62nd |
Industry group Drugs | 610 out of 1,730 | 65th |
Industry Pharmaceutical Preparations | 481 out of 1,329 | 64th |
Source: SEC filing on March 25, 2019.
Silvernail's colleagues
We found three more compensation records of executives who worked with Lauren P. Silvernail at Revance Therapeutics in 2017.